Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside
© Mario Tama / Getty Images News via Getty Images
Our Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) 24/7 Wall St. price target lands at $261.72, pointing to 11.28% upside from the current price of $235.18. Our recommendation is buy, and our model carries a 90% confidence level. JNJ has quietly become one of healthcare’s most reliable compounders again, with oncology firing and dividend support intact.
| Metric | Value |
|---|---|
| Current Price | $235.18 |
| 24/7 Wall St. Price Target | $261.72 |
| Upside | 11.28% |
| Recommendation | BUY |
| Confidence Level | 90% |
A Quiet Rally Into New Highs
JNJ has run hard. Shares are up 14.91% year to date and 55.3% over the past year, currently trading about 1% below the 52-week high of $250.24. The latest Q1 2026 earnings report backed the move. Revenue rose 9.9% to $24.062 billion, and adjusted EPS of $2.70 beat estimates for the fourth consecutive quarter.
Management raised 2026 guidance to $100.3B to $101.3B in sales and $11.45 to $11.65 in adjusted EPS. Recent catalysts include a $1 billion Vision manufacturing expansion in Jacksonville, the $1 billion Firefly Bio acquisition adding a degrader-antibody-conjugate platform, and a Talvey late-stage trial showing up to 53% mortality risk reduction in multiple myeloma.
Why Bulls See a Breakout Toward $275
The bull case rests on oncology and immunology firing simultaneously. DARZALEX hit $3.964 billion (+22.5%), TREMFYA reached $1.608 billion (+68.3%), CARVYKTI grew 62.1%, and RYBREVANT/LAZCLUZE jumped 82.7%. Cardiovascular MedTech grew 13.0% on Abiomed and Shockwave.
The analyst consensus target of $252.87 sits between our base and our bull case of $273.48 over the next year. If the DePuy Synthes orthopaedics spin lifts the remaining mix toward double-digit growth, the multiple can expand from the current forward P/E of 20x.
The Risks Worth Watching
The bear case is real. STELARA fell 59.7% in Q1 on biosimilars, dragging Innovative Medicine by roughly 920 basis points. Litigation charges of $330 million in Q1 followed $854 million in Q4 2025, and talc cases remain an overhang.
Our bear scenario lands at $222.46, a 5.41% drawdown. That said, bulls would argue the headline net income decline of 52.4% reflects those non-recurring legal charges rather than underlying operating performance, where adjusted EPS still grew and guidance was raised.
Our Take on JNJ Here
The 24/7 Wall St. price target of $261.72 and buy rating reflect a balanced setup: defensive characteristics, accelerating top-line growth, and a pipeline that should outrun the STELARA cliff. The setup favors investors seeking healthcare exposure with a 0.26 beta and a 64-year dividend growth streak.
The case weakens if talc litigation reserves expand materially or if the orthopaedics separation slips beyond the 18 to 24 month window. Our 90% confidence is high for a reason: this is a low-volatility blue chip with a clear growth narrative.
JNJ Price Prediction 2026-2030
Looking further out, here is where our model projects Johnson & Johnson could trade, assuming current growth trajectories and the planned orthopaedics separation execute on schedule.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $248.24 |
| 2027 | $273.86 |
| 2028 | $294.53 |
| 2029 | $315.88 |
| 2030 | $333.63 |
These projections assume JNJ continues executing on oncology and cardiovascular MedTech. Significant upside or downside could result from talc litigation outcomes or the pace of double-digit growth promised by end of decade.
